Prefix Capital

Prefix Capital operates as a San Francisco-based venture capital firm founded in 2019, carving out a distinctive position in the early-stage deep technology landscape. Unlike commodity-focused funds that spread bets across sectors, Prefix Capital concentrates on what partners Byron Alsberg and Owen Van Natta call 'foundational technologies' — the underlying infrastructure layer that enables downstream innovation across AI, semiconductors, and biotechnology.

The firm's origins trace to Alsberg's experience building semiconductor businesses at Texas Instruments and voice technology at Audience, before co-founding two startups that were eventually acquired by public companies. This hands-on operator background shapes how Prefix Capital evaluates deep-tech opportunities and supports portfolio founders through the lengthy development cycles inherent to foundational technology companies.

Van Natta brings a different but equally relevant pedigree — prior roles working directly with Jeff Bezos, Mark Zuckerberg, Rupert Murdoch, and Pincus Ventures gave him exposure to how technology platforms scale. Founding Principal Calvin Ling rounds out the team with Honda Silicon Valley Lab experience, handling due diligence and investment operations. The combination of semiconductor veterans, platform-scale operators, and deep-tech engineers creates a firm unusually suited to evaluate companies building at the hardware-software intersection.

Prefix Capital typically writes checks in the $1M to $5M range for seed and Series A investments, with the flexibility to lead or co-lead rounds depending on opportunity size. The firm prefers to maintain active involvement post-investment, providing technical architecture guidance and connecting founders with the engineering talent pipelines that deep-tech companies need to scale.

The firm's portfolio spans 20 companies across AI acceleration, synthetic biology, advanced materials, and computational infrastructure — a deliberate mix designed to create portfolio synergies as these foundational technologies mature and intersect.

For founders building at the intersection of hardware and software, or developing enabling technologies for AI and biotech, Prefix Capital offers something increasingly rare in venture capital: partners who have literally built the systems they now invest in.

Prefix Capital's investment thesis centers on 'foundational technologies' — the underlying innovations that other companies build upon. The firm explicitly avoids me-too software plays and instead targets companies developing core enabling technologies in AI acceleration, semiconductor alternatives, synthetic biology, and computational infrastructure.

The founding partners developed this thesis through personal experience. Byron Alsberg watched how semiconductor advances unlocked new computing categories. Owen Van Natta observed how platform businesses scale across networks. Both concluded that the most consequential venture returns come from owning the infrastructure layer, not the application layer above it.

Within deep technology, Prefix Capital shows particular interest in companies addressing AI's computational demands — whether through novel chip architectures, cooling systems for dense compute farms, or alternative computing paradigms like diamond-based processing. The firm also tracks synthetic biology companies that apply engineering principles to biological systems, and advanced materials innovators rewriting what's possible in semiconductor fabrication.

Investment criteria emphasize technical defensibility above all. Prefix Capital looks for companies with proprietary approaches that competitors cannot easily replicate — whether through patents, trade secrets, or simply the accumulated engineering complexity that early-movers build over time. The team evaluates whether the technology represents genuine advancement, not incremental improvement on existing approaches.

Team quality matters profoundly in deep tech investing, and Prefix Capital prefers founders who have spent years inside the domain they're addressing. A semiconductor materials startup led by former Intel process engineers signals different risk profiles than one led by software entrepreneurs pivoting into hardware. The firm's technical due diligence probes founder depth extensively.

Market timing distinguishes Prefix Capital's approach from pure academic deep-tech funds. The partners look for 'inflection point' opportunities — moments when a foundational technology becomes economically viable or when regulatory shifts open new markets. Lemonaid Health's trajectory, for instance, benefited from expanding telemedicine acceptance alongside the team's digital health infrastructure.

Prefix Capital has continued deploying capital into deep-tech infrastructure despite broader venture market volatility. The firm's deal activity reflects commitment to its foundational technology thesis rather than drift toward safer software bets during market corrections.

Recent investments show increasing attention to AI infrastructure companies as enterprise AI adoption accelerates. The firm sees AI compute demand outstripping available GPU supply, creating opportunities for alternative acceleration approaches and better cooling solutions for dense compute deployments.

The synthetic biology subset of the portfolio has attracted follow-on investor interest as biomanufacturing scales. Manus Bio, which applies engineering principles to biological systems for sustainable chemical production, exemplifies the firm's interest in companies that use biology as a precision manufacturing platform rather than merely a research tool.

Prefix Capital maintains a deliberate pace — approximately 4-6 new investments annually — which allows the partners to provide meaningful support to each portfolio company. The firm resists the temptation to build enormous portfolios that diffuse partner attention across dozens of companies.

Co-investment relationships with other deep-tech funds have expanded as Prefix Capital's reputation in the sector has grown. The firm now frequently co-invests with strategic corporate venture arms from semiconductor and biotech companies, as well as growth-stage funds that prefer Prefix Capital's early technical diligence.

The partners have deliberately avoided sector drift toward hot themes like consumer apps or crypto infrastructure, maintaining focus on 'boring' infrastructure that enables other industries to function. This consistency has attracted LPs seeking pure-play deep-tech exposure.

Prefix Capital's portfolio reflects deliberate diversification across foundational technology subsectors, with each company attacking a different bottleneck in computing, health, or materials science infrastructure.

Diamond Foundry stands out as perhaps the most distinctive portfolio company — developing diamond-based computing substrates that offer superior thermal conductivity for high-performance chips. The company's technology addresses heat dissipation challenges that copper-based solutions cannot adequately solve as chip densities increase. Prefix Capital led Diamond Foundry's early rounds, attracted by the team's deep materials science expertise and the clear application to AI compute demand.

Tractable has achieved notable scale in applying computer vision to insurance claim processing — analyzing vehicle damage photographs to accelerate claims workflows for major insurers. The company's AI platform processes millions of claims annually across multiple geographies, demonstrating how deep-tech infrastructure can penetrate traditional industries.

Lemonaid Health represents the firm's digital health exposure, operating a telemedicine platform that combines convenient prescribing with affordability. The company's growth trajectory benefited from both the shift toward telehealth and the team's focus on building medical infrastructure that scales across state regulations.

Ample tackles EV charging infrastructure with a novel approach to battery swapping and charging network design. The company's approach to EV energy delivery addresses consumer adoption barriers that traditional charging station models have struggled to solve.

Manus Bio produces specialty chemicals through precision fermentation — using engineered microorganisms as living factories rather than traditional chemical synthesis. The approach offers dramatic environmental improvements and supply chain resilience compared to petrochemical-dependent alternatives.

The firm's portfolio also includes Aligned Carbon (carbon nanotube technology), Neocortix (mobile computing platforms), Symmetry Systems (data security), and Prellis Biologics (protein synthesis). Collectively, the portfolio spans 20 companies addressing different infrastructure bottlenecks across computing, health, and materials.

Prefix Capital evaluates deep-tech opportunities against a specific set of criteria developed from the partners' operator experience, emphasizing technical defensibility and realistic deployment timelines.

The first evaluation dimension is technological differentiation — does the company possess something genuinely difficult to replicate? Prefix Capital looks for approaches that require years of accumulated expertise, not easily reverse-engineered algorithms. Patent portfolios provide some protection, but the team understands that deep-tech defensibility often comes from tacit knowledge embedded in engineering teams rather than legal constructs.

Second, the firm assesses market timing rigorously. Deep-tech companies face longer development cycles than software startups, which means market window miscalculations can prove fatal even with superior technology. Prefix Capital probes whether the target application has reached an inflection point where economics or regulation supports adoption.

Team composition receives extensive scrutiny. Deep-tech hardware and biology companies require different founding team profiles than pure software plays. Prefix Capital looks for domain experts who have spent years inside the specific technology they're commercializing, not entrepreneurs who discovered a technical opportunity and are now attempting to build expertise.

Capital efficiency in deep tech presents distinct challenges that Prefix Capital understands intimately. The firm evaluates whether founders have realistic appreciation for the capital required to reach technical milestones — hardware and biology paths to revenue typically demand more capital and time than software equivalents.

Finally, the firm assesses strategic optionality — whether the company's technology could serve multiple downstream applications or whether it depends on a single use case. Foundational technologies with multiple application paths tend to generate more durable venture returns.

Founders who understand these nuanced criteria and can speak to them directly tend to advance further in Prefix Capital's process than those who present generic pitch decks without deep-tech-specific content.

Prefix Capital receives deal flow primarily through its deep-tech network — introductions from university research labs, semiconductor industry veterans, and founder referrals within the portfolio. Cold outreach works poorly unless accompanied by exceptional technical credentials.

The most effective approach involves warm introductions from individuals trusted by the partners — whether fellow founders in the Prefix Capital portfolio, engineers at major technology companies, or investors who specialize in the same subsector. The firm's technical reputation means that engineering-grade endorsement from credible sources carries significant weight.

For cold outreach, founders should lead with technical specificity — not marketing language. Prefix Capital's partners can evaluate technical claims directly and respond to poorly substantiated assertions immediately. The best cold emails include detailed technical differentiation, clear explanation of why current approaches are inadequate, and specific data on development progress.

Preparation for meetings with Prefix Capital should include readiness for deep technical due diligence. The partners will probe technology claims, probe team expertise in detail, and challenge assumptions about deployment timelines. Being defensive or vague about technical details signals inadequacy rather than confidentiality.

Follow-up persistence should be measured — the firm's small investment pace means limited bandwidth for rapid responses. A single follow-up demonstrating meaningful progress (technical milestone, new technical hire, strategic partner signed) performs better than repeated 'just checking in' messages.

Building credibility in the relevant technical community before approaching Prefix Capital improves outcomes substantially. Conference presentations at domain-specific venues, publications in technical journals, and GitHub contributions for software infrastructure all signal technical legitimacy that the partners can independently verify.

Deep-tech companies face capital requirement profiles that differ substantially from software startups, and Prefix Capital expects founders to understand these mechanics before fundraising. Hardware and biology development paths typically require $15M to $50M to reach revenue-generating milestones, compared to $3M to $10M for software equivalents.

Financial projections for deep-tech companies should account for extended development timelines, regulatory approval processes where applicable, and the capital equipment costs that hardware and biotech companies face. Naive application of software-style 'growth at all costs' mentalities tends to destroy deep-tech ventures by exhausting capital before technology reaches market readiness.

Working with a fractional CFO experienced in deep-tech finance significantly improves fundraising outcomes. Such professionals understand how to present technical development milestones in language that resonates with deep-tech investors, translate capital efficiency into investor-return scenarios, and model realistic paths to unit economics at scale.

Deep-tech companies typically require staged financing aligned with technical milestones rather than growth metrics. Presenting a fundraising timeline tied to specific technical achievements (tape-out, clinical trial phases, scaling milestones) signals operational maturity to investors like Prefix Capital who have watched many deep-tech companies consume capital without reaching inflection points.

Key metrics for deep-tech pitch presentations include capital per milestone, technical risk remaining, regulatory pathway clarity, and defensibility assessment. These differ substantially from software metrics like MAU growth or viral coefficients, and presenting software-style metrics to deep-tech investors signals inexperience.

Understanding the difference between hardware/biotech financials and software financials is essential for any founder approaching deep-tech-focused investors. Prefix Capital particularly appreciates founders who demonstrate this awareness through their financial modeling.

Whether you're preparing to pitch Prefix Capital or other deep-tech VCs, financial foundations built for hardware-scale timelines and biology-scale capital requirements set you apart from founders who apply software mentalities to deep-tech opportunities. Our team has guided numerous deep-tech founders through successful fundraising rounds and can help you construct capital-efficient narratives aligned with your technical milestones.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you're looking for seed-stage investors or growth equity firms, you'll find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage.

For more information about Prefix Capital's investment approach and portfolio, visit the firm at https://www.prefixcapital.com